Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. by Lubahn, D. B. et al.
Proc. Natl. Acad. Sci. USA
Vol. 86, pp. 9534-9538, December 1989
Medical Sciences
Sequence of the intron/exon junctions of the coding region of the
human androgen receptor gene and identification of a point
mutation in a family with complete androgen insensitivity
(X chromosome/polymerase chain reaction/steroid receptor/testicular feminization/male pseudohermaphroditism)
DENNIS B. LUBAHN*tf, TERRY R. BROWN§, JORGE A. SIMENTAL*t, HENRY N. HIGGS*t,
CLAUDE J. MIGEON§, ELIZABETH M. WILSON*t¶, AND FRANK S. FRENCH*tII
*Laboratories for Reproductive Biology and the Departments of tPediatrics, tPathology, and IBiochemistry, University of North Carolina, Chapel Hill,
NC 27599; and §Department of Pediatrics, Division of Pediatric Endocrinology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205
Communicated by Mary Ellen Jones, August 25, 1989 (received for review July 5, 1989)
ABSTRACT Androgens act through a receptor protein
(AR) to mediate sex differentiation and development of the
male phenotype. We have isolated the eight exons in the amino
acid coding region of the AR gene from a human X chromosome
library. Nucleotide sequences of the AR gene intron/exon
boundaries were determined for use in designing synthetic
oligonucleotide primers to bracket coding exons for amplifica-
tion by the polymerase chain reaction. Genomic DNA was
amplified from 46,XY phenotypic female siblings with com-
plete androgen insensitivity syndrome. AR binding affinity for
dihydrotestosterone in the affected siblings was lower than in
normal males, but the binding capacity was normal. Sequence
analysis of amplified exons demonstrated within the AR ste-
roid-binding domain (exon G) a single guanine to adenine
mutation, resulting in replacement of valine with methionine at
amino acid residue 866. As expected, the carrier mother had
both normal and mutant AR genes. Thus, a single point
mutation in the steroid-binding domain of the AR gene corre-
lated with the expression of an AR protein ineffective in
stimulating male sexual development.
cell cultures (23-25). However, the study of natural muta-
tions allows correlations not only between structure and
function but also between structure and phenotype. For
example, the molecular nature of a mutation in the AR gene
has been recently reported in a family found to have a
deletion of the entire steroid-binding domain (26) associated
with loss of androgen-binding activity and complete AIS.
Identification of natural gene deletions and point mutations
offers an opportunity to study structural alterations in AR
that affect sex differentiation, development, and reproduc-
tive function.
In this study, our aims were to determine the location of the
hAR gene splice sites for comparison with other steroid
receptors and to obtain the intron sequences flanking each
exon to enable us to design oligonucleotide primers for exon
DNA amplification by using the polymerase chain reaction
(PCR) (27). Amplification of exons made it possible to
sequence the AR gene- coding regions of affected individuals
in a family with complete AIS (28, 29) and revealed a single
point mutation within the steroid-binding domain.
Androgens act through a receptor protein to promote differ-
entiation and development of the male phenotype (1, 2). The
androgen receptor (AR) is a member of the steroid receptor
family, which is part of a larger nuclear receptor superfamily
(3-5). These receptor proteins are related by sequence sim-
ilarities within their "zinc finger" DNA-binding domains and
by ligand-dependent regulation of specific gene transcription
(3-5). Complementary DNAs of many members of the nu-
clear receptor family have been cloned (refs. 3-5 and refer-
ences therein and ref. 6), including the human receptors for
thyroid hormone, retinoic acid, vitamin D, glucocorticoid,
progesterone, mineralocorticoid, estrogen, and androgen (7-
13). Genomic clones have been described for the human
estrogen (14), human vitamin D (15), chicken thyroid hor-
mone (16), and chicken progesterone (17) receptors. To
further understand the evolution and function of steroid
receptors in eukaryotes and to identify mutations in the
human AR (hAR) gene that cause the androgen insensitivity
syndrome (AIS), we undertook to clone the AR gene.**
In 46,XY individuals, X chromosome-linked androgen
insensitivity results in a spectrum of developmental abnor-
malities ranging from a complete external female phenotype
to partially masculinized ambiguous genitalia (1, 2, 18-21)
and may include some infertile males with apparently normal
genitalia but defective spermatogenesis (22). Mutations pro-
duced in vitro have allowed structure-function analyses of
nuclear receptors by examining effects of these mutations in
MATERIALS AND METHODS
Isolation and Analysis of hAR Genomic Clones. Exon spe-
cific oligonucleotide probes were located within the AR
cDNA by comparison of the hAR amino acid sequence (10)
with the gene structure and amino acid sequence of the
chicken progesterone receptor (cPR) (17). These exon spe-
cific oligonucleotides and hAR cDNA fragments were used as
probes to identify four genomic clones from a partial Sau3A,
bacteriophage A Charon 35, flow-sorted, X chromosome
genomic library (XLAOXNLO1, obtainable from the Amer-
ican Type Culture Collection). Exons C-H, contained within
the clones, were isolated, subcloned, and sequenced as
described for the isolation of exons A and B (7, 10). Exon
sequences ofhAR were compared with exons of other steroid
receptors by the GCG alignment program (30).
Experimental Subjects. Informed written consent was ob-
tained from each individual according to The Johns Hopkins
Institutional Guidelines for Clinical Investigation. The three
affected 46,XY siblings with complete AIS and their mother
have been described (28, 29, 31, 32). The affected siblings had
normal female external genitalia with absence of uterus and
fallopian tubes. A short vagina ended in a blind pouch.
Abbreviations: AR, androgen receptor; ER, estrogen receptor; GR,
glucocorticoid receptor; PR, progesterone receptor; MR, min-
eralocorticoid receptor; h, human; c, chicken; PCR, polymerase
chain reaction; AIS, androgen insensitivity syndrome.
'lTo whom reprint requests should be addressed.
**The sequences of the hAR coding exons (A-H) and flanking intron
regions reported in this paper have been deposited in the GenBank
data base (accession nos. M27423-M27430, respectively).
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Bilateral testes were present intraabdominally but there were generate fragments of approximately 190-500 base pairs to
no Wolffian duct derivatives other than vestigial vasa defer- facilitate isolation of fragments from agarose gels for subse-
entin. Breast development occurred spontaneously at pu- quent sequencing. The oligonucleotides were designed also
berty and there was only sparse pubic and axillary hair to permit detection of possible splice site mutations and to
despite blood testosterone concentrations in the normal adult avoid repetitive sequence homologies. Oligonucleotides
male range. ranging in size from 20 to 30 bases were synthesized on the
Amplification of AR Exons via the PCR and Sequence DNA Synthesizer model 380A from Applied Biosystems and
Analysis. Amplification of the coding region of hAR was were used without further purification. Genomic DNA (1 g)
performed as recommended by Cetus. Twelve pairs of oli- was amplified through 30 cycles in a 100-,ul vol of 50 mM
gonucleotide primers (underlined in Fig. 1) were selected to KCI/15 mM MgCl2/0.1% (wt/vol) gelatin/10 mM Tris HCI,
Al--->A EXON Coding Re ionCGCCTGTTGAACTCTTCTGAGCAAGAGMGGGGAGGCGGGGTAAGGGAAGTAGGTGGAAGATTCAGCCAAGCTCAAGGATGGMGT AGTTAGGCTGGAAGGGTCTACCCTCGGCCG 1
MetGLuVa nLeuG yL y ArgVa TyrProArgPro 14
CCGTCCAAGACCTACCGAGGAGCTTTCCAGAATCTGTTCCAGAGCGTGCGCGAAGTAT GCACCCAGAGGCCGCGAGCProSerLysThrTyr rgGlyA aPheGlnAsnLeuPheGlnSerVa LArga luVa LI eGlnAsnProG LyProArgHisProGLuALaAL aSerALaAL aProProG lyA aSerLeu
CTGCTGCTGCAGCAG C-AG G AGCAGCAG AG AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAAGAGAgTAGCCCCAGGCAGCAGCAG tG EG GffTGAGGATGTTCT 360LeuLeuLeuGlnGLnGLnGnGL~ LnGLnGlnGLnGnGLnGLnGLnGlnGLnGLnGtnGlnGLnGL nGlnGluThrSerProArgGLnGLnG nGLnGLnULnGLyGluAspG yber 94
CCCCAAGCCCoTCGTAGAGGCCCCAAGGCTACCTGGTCTGGATGAGGAACAGCACCTTCACAGCCGCAGTCGGCCCTGGAGTGCC CCCCGAGAGAG T GCGTTCCAGAG CTProGlnA laHlsArgArgG UyPryeUrrrspuLuLUaLUntrwroSierulnrroGLnSerAlaLeuG LuCysH1sProGLuArgGly~ysValPro~luProGLy 134
GiCGiaCGTGrrCG ,CCAGCAAGGGGCTGCCGCAGEAGCTGCAGCACCTCCGGACG TGACTCAGCTG CCCATCCACGTTGTCCCTGCTGGGCCCCACTTTCCCC CTTAAGCAGC 600A aA aVa lA aA taSerLysG yLeuProGI tnLleuroA LaProProftp luspAspSerA laA laProSerThrLeuSerLeut euGtlyProThrPhero lyLeuSerSer l7
TGCTCCGCTGACCTTAAAGACATCCTGAGCGAGGCCAGCACCATGCAACTCCTTCAGCAACAGCAGCAGeGAuGGTATCCGAAGGCAGCAGCAGCGGGAGAGCGAGGGGGCTCGGGG zoCgsSerALaAspLeuLysAspI LeLeuSerGluALaSerThrtetGtnLeuLeuGl nGlnGlnGlnGLnGLuAlavak erGLuGLySerSerSerGL yArgAiaArg luAlaSerGly 214
GTCCCACTTCCTCCAAG~CAATWTACTTAGG CAgTTCGACCATTTCTGACAACGCAAGGAGTTGTGTAAGGCAGTTCGGTGTCCATGGCCTG TGTGMarrolirberberLysmspsnIyr euG yGyT rSerThrl LeSerAspAsnALNLysI LUeLewysLysVravalSerVaLSer~etG yLeuGlyVa aLe ktuG sZ
CTGAGT CCAGGGGAACAeGCTTCGGGGGGATTGCATGTACGCCCCACTTTTGGGAGTTCCACCCGCTGTGCGTCCCAITCCTTGTGCCCCATTGGCCGAATGCAAAGGTTCTCTGCTAGAC 260LeuSer roGlyGLuG lnLeuArgG IyAspCysMetTyrA LaProLeuLeuG lyVa lProProAlaVaLArgProThrProCysA LaProLeuAiaGIuCysLysG IyserLeuLeuAsp
GACAGCGCAGGCAAGAGCACTGAGATAgTGCTG^GTATTCCCCTTTCAAGG A TTACACCAAAGGGCTAGAAG CGAGAGCCTA GCGC CTaGCAGCGCTGCAGGGGAGCTCC 1 80AspSerA t aGLyLysSerT rGLuAspTh rA laG uTyrSerProPheLysG lyGIyTyrThrLysG Le lyG luSerLeuG yyysSerG ySerA a aA laGlySerSer 334
GGGA ACTTGAACTGCCGTCTA CCTGTCTCTCTACAAGTCCG AGCACTGGACGAGGCAG TG GTACCAGAGTCGCGACTACTACAACTTTCCACTGGCTCTGG CGACCGCCGCCC 12(4G yTnrLeuG luLeuProSerTrLeuSerLeuTyrLysSerG yyArLeuAspGuALaAlaA'aTmn rs leuAs eLeuA a yProProPro3
CCTCCGCCGCCTCCCCATCCCCACGCT GCAICAAGCTGGAGAACCCGCTGGACTACGGCAGCGCCTGGGCGGCTGCGGCGGCGCAGTGCCGCTATGGGGACCTGGCGAGCCTGCAiTGGC 1ProProProProProHi sProHisA aArg9ITeLytLeuLuA3MPrTLeuAspTyrG lySerAL aTrpALaALAlaAlaA L aG nCysArgTyrG yAspLeuA LaSerLeuHiSGly 414
GCGGGTGCAGCGGGACCCGGTTCTGGGTCACCCTCAGCCGCCGCTTCCTCATCCTGGCACACTCTCTTCACAGCCGAA GCCAGTTGTATGGACCGTGTGGTGGTG TGTGGGTGGT 14&0AlaG yALaALaGLyProGtySerGLySerProSerA LaALaALaSerSerSerTrpHisThrLeuPheThrA LaGLuGuGI yGLnLeuTyrGLyProCysGLyGLyGlyGLyGLyGLy
GGCGGCG CGGCG CCGCGGCGGCGGCGGC CG CGCG CGCGCGCCGAGGCGGGAG TGTAGCCCCTACGGCTACA TCGGCCCCCTCAGGGGCTGGCGGGCCAGGAAAGC 1
GCyGLyGLyGyGLyGlyGLyGLyG yGtyGLyGlyGlyG yGGyGGuALa yGaVaL AaProTyrGLyTyrThrArgProProGlnGLyLeuA aGLyGLnGluSer
GACTTCACCGCACCTGATGTGTGGTACCCTGGCG CATGGTGAGCAGAGTGCCCTATCCCAGTCCCACTTGTGTCAAAAGCGAAATGGGCCCCTGGATGGATAGCTACTCCGGACCTTACX~pnenV LnPtr yr~~rrG ytyetva ziernrgva -oyrrbep -P roG l y l y~~~~~~~e o~~h r~~x~t~lLysSerGWMly roTrp~etAspSerTyrSerG lyProtyr53
GGlGACATGCGGTAAGTTTTTCCTTCCAGAAATGTCGCCTTTCGGCCCAGGGCAGAGTCACTCTGTGTTCTGG ........... GCCTGCAGGTTAATGCTGAAGACCTGAGACTTCACT 1 19
TGCCTATTTCTGCCATTCAGTGACATGTGTTGCATTGGTTTTTTGTGTCTTTCCAGTTTGGAGACTGCCAGGGACCATGT TTTGCCCATTGACTATTACTTTCCACCCCAGAAGACCTGC 1909
gLeuGluT rA aArgAspHisVa LeuProl IesiTyrTyrPheProProGLnLysTh rCys
CTGATCTGTGGAGATGAAGCTTCTGGGTGTCACTATG AG TCTCACATGTGGAAGCTGCAAGGT TTCTTCAAAAGAGCCG TGAAGGTAAAGGGTCTTGCACATGCACTTCTCTTTCC 2Q?9Leul eCysG lyAspGluA IaSerG yCysHisTyrG lyAl aLeuThrCysGtySerCysLysVa I PhePheLysArgA I aA aGluG- 2 C 588
CTTTCTTCTCCGGGAAATACTTAGGCAGATTTCTTAAATGGTATGAAGCTACATACTG ....GTTTGGTGCC 2142
EXON
CTCCCAGTGAAACAGAAGTACCACTGCGCCAGCAGAAATGATTGCACTATTGATAAATTCCGAAGGAAAGATTGTCCATCTTGTCGTCTTCGGAAATGTTATGGAAGGATGAGCTTCTG 2382-lyLysG nLysTyrLeuCysA aSerArgAsnAspCysTnr I tLeAspLysPheArgArgLysAsnCysProSerCysArgLeuArgLysCysTyrGluA ayGetT rLeur6er




TCTAGACACAGGCTGACCCTTTCATAGGCAACGTGGCCATCAG .......................... GGAGTTTAGAGTCTGTGACCAGGGAGAATGGTGATTTTCTTAGCTAGGGCAGTTTTTCTAAAAAGGT 2612
- EXON
AGTTGAGCATTGTGTTTTTGACCACTGATGATAAATTCAAGTCCTCTTCCTTACCCAATGCCGGAAGCTGAAGAAACTTGGTAATCTGAAACTACAGGAGGACAGTGGA CTTCCAGC 27302
l aArgLysLeuLysLysLeuG lyAsnLeuLysLeuGlnG luG luGlny a lAslaSerSer 64
ACC§CtGGCCCCATGACCCCTAATCGA GCTGCCGAC TGTGGTGGTGGGG GTGCAGGAATCTCTGGGCTTAGTTGTAAATGTCCC 3311
gCCGAAGCTGAAGTTCACCA GCTATGATGTCAGCCCACTTTCTGAATGTCCTGGTCCAGAG ATGTA TCThrT r erProT rGluGLuThr rMnLysLeuThrVa SerHsls tel~yTyrG uCysGlnProl tePheLeuAsnVaLLeuG alua leGluWro~yValVaLCysAla68
GCATACGACAACAACCAGCCCGACTCCTTT.GCAGCTTGCTCTCTAGCCTCAATGAACTGGGAGTGAGACAGCTTGTACACGTGGTCAAGTGGGCCAAGGCCTTGCCTGGTAAGGTAAG 232G tyH isAspAsnAsnG lnProAspSer>§eA laA laLeEul!yuerSerLeLAsnG luLeuG lyG luArgG lnLeuVaIlH isVa lVa l Ls~xrgA laLysA [aLeuProG 72
GGAAGTG AG ATGA TAAGGGGGATt ......... CAACCCGTCAGTACCCAGACTGACCACTGCCTCTG CTCTTCTTCT GCAGGCTTCCGCAACTTACATCGTGG CGACCAGATG 3083
=yPheArgAsnLeu~l sVa AspAspGlnt~et n34
GCTGTCAG TCCAGTACTCCTGGATGGGGCTCATGGTGTTTGCCATGGGCTGGCGATCCTTCACCAATGTCAACTCCAGGATGCTCTACT TCGCCCCTGATCAATCCCAATCCTGCTA 392QA LeVaI GnTyrSeTrpMetGlyLeuMetVaLPheAlaMetGLyTrpArgSerPheThnrAsnVa lAsnSerArgMetLguTyrPheAlaPryLApLuValnPfhesnGl- 771
intron5 <-----Einton!< --G Hi
CTCCTnGGGCCCAGACCTCACTAAAATACAGCAGCT TEGGC"CAGACCTGGTTGGTGGTGATGGTGATGGGGTGAcAGTGAAGCT .................................................... CTCTGGGCTTATTGGTAAACTTCCC 331 1
ProGlnGluPheLeuCysMetLysL euLeue uPerja~ In G C
CATTATTAGGGAAAAGCCAGCTCCTGGAC ......... CTTTCAGATCGGATCCAGCTATCCTTTCCCCTGAGATCTCCCTGACAGACTGAGGCCCCAAGCACACAGACTTCAACTAAC 3662
AGGAAGCCAEAGT"AGAT GGTTCCCTGTGGGGGT GGGGGTCAAGTCTGTGGTCAGAAAACT TGGTGCTTTGTCTAATGCTCCTTCGTGGGCATGCTT CCCCTCCCCATTCTGTCTTCATCCC 3782
AC:ATCAG TCCAGTGGATGAGCT GAAAAATCAAAAATTCTTTGATGAACTTCGAATGAACTACATCAAGGAACTCGAT CGTATCATTGCATGCAAAAGAAAAAATCCCACAT CCTGCTCA 39n2eProVa lAsp lyLeuLysAsnG lnLysPhePheAspG lvneu~rAgtjetAsnTyrl IeLysG luLeuAspArgIleI teA LaCygjysArgLysAs~nlProhe~s 5
AGACGCTTCTACCAGCTCACCAAGCTCCT GGACTCCGTGCAGCCTGTAAGCAAACGATGGAGGGTGCT TTATCAGGGAGAACAGCCTGATAGAG ................................................... GAGGCCACCTCCTTGT 4012ArgArgPheTyrG lnLeuThrLysLeuLeuAspSer~a xGlnPro=-6
CAACCCT GTTTTTCTCCCTCTTATTGTTCCCTACAGAT TGCGAGAGAGCTGCATC GTTCACTTTTGACCTGCTAATCAAGTCACA.CATGGTGAGCGTGGACTT TCCGGAAATGATGGCA 4132
I teA taArgGluLeuHilsGPlheThrPheAspLeuLeuIl eLysSerHilsMetVa lSerVa lAspPheProG luMetMetAla 896
IGAGA CAACTCTGTGCjAGTGCCCAAGATCCTTTCTGGGAAAGTCAAGCCCATCTATTTCCACA CCCGTGAAGCAT TGGAAACCCTATTTCCCCACCCCAGCT CATGCCCCCTTTCAGA 425
GM el eSerVaGInVaGProLysLeLeuSerG~yLysVaLLysPro1eT rPheHisThrGlnEnd
TGTCTTCTGCCTGTTATAACTCTGCACTACTCCTCTGCAGTGCCTTGGGGAATTTCCTCTATTGATGTACAGTCTGTCATGAACATGTTCC 4343
FIG. 1. Sequence of hAR gene intron/exon splice sites. Oligonucleotides used for PCR are underlined, with orientations indicated by arrows.
Gaps in sequence (indicated by dots) are undetermined intron sequence. Canonical donor and acceptor splice sites are double underlined. Point
mutation found in the G exon is marked by an asterisk.
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pH 8.3/200 ,M each of the four deoxyribonucleotides.
Thermus aquaticus DNA polymerase (Taq polymerase) (3.75
units) (Cetus) and each oligonucleotide at 20 AM were used
per reaction. Amplification conditions consisted of an initial
denaturing step at 950C for 5 min, annealing at 600C for 1 min,
and polymerization at 720C for 6 min, followed by 30 cycles
of 950C for 30 sec, 60'C for 1 min, and 720C for 6 min with a
3-sec increment per cycle in polymerization time. For oligo-
nucleotide pairs A7-A8 and A9-A10, an annealing tempera-
ture of 650C reduced the number of nonspecific fragments. In
addition, 60 cycles were used for oligonucleotide pair A7-A8,
which amplifies a fragment with high G+C content. Ampli-
fied fragments of the correct size were ligated into blunt end
M13 vectors and sequenced (7, 10). Errors due to Taq
polymerase misincorporation were detected by sequencing
two independent clones of each orientation.
RESULTS AND DISCUSSION
Six genomic clones containing exons ofthe amino acid coding
regions of the hAR gene were isolated from a human X
chromosome A library by using hAR cDNA and synthetic
oligonucleotide probes. Although the genomic clone inserts
averaged 15 kilobases (kb) and the mRNA ofhAR was 10-11
kb (7, 9, 10), only exons D and E and exons F, G, and H were
found in the same clones (data not shown). Calculations
based on five nonoverlapping clones averaging 15 kb yielded
a size estimate of >75 kb for the hAR gene. Sequences of the
hAR coding exons and flanking intron regions are shown in
Fig. 1. Cloned genomic exon and flanking intron sequences
were confirmed by sequencing PCR amplified fragments of
genomic DNA. Development of a method utilizing PCR for
rapid analysis of mutations in the coding regions of the AR
gene required that we sequence only far enough into the
flanking introns to allow selection of suitable synthetic oli-
gonucleotide primers to bracket each exon. Thus, the large
central regions of each intron remain to be sequenced.
N-Terminal
Exons A
With the determination of the intron/exon splice junction
sequences, both evolutionary and functional analyses of the
hAR and its mutations are now possible. The intron/exon
boundaries have the canonical splice consensus sequences
(double underlined in Fig. 1) (33). Splice sites of the hAR gene
and those ofhuman estrogen receptor (hER) (14) and cPR (17)
genes are remarkably similar in location and flanking amino
acid sequences (data not shown). By comparison with other
homologous steroid receptor cDNAs and cloned steroid
receptor genes (hAR, cPR, hER, and hMR) (MR, min-
eralocorticoid receptor), the probable splice sites of the other
as yet unreported steroid receptor gene sequences (hPR,
hMR, and hGR) (GR, glucocorticoid receptor) could be
predicted. Comparisons of their exons reveal regions of
evolutionary conservation of essential functions (Fig. 2).
The most highly conserved exons, B and C, encode the first
and second zinc finger motifs, respectively, and make up the
DNA-binding domain (3-5). Within these and other exons,
sequence identity of hAR is closer to hPR, hMR, and hGR
than to hER (Fig. 2). Only the second zinc finger exon of
hER, exon C, has a high degree of sequence similarity with
hAR. The large N-terminal domain contained within the A
exon has little similarity with other receptors. This exon
appears to contain a transcription-enhancing function and
may also modulate DNA binding (3-5). Neither exon A nor
exons B and C are known to have any influence on ligand
binding.
In the ER and GR, it has been demonstrated that the
steroid-binding domain encompasses exons E-G and por-
tions of exons D and H (23, 24). hAR exons E-G exhibit a
relatively high degree of similarity to hPR, hMR, and hGR
(Fig. 2). Although exon D is less homologous overall, a
23-amino acid region positioned near its 3' junction is highly
conserved among all nuclear receptors (10). Experimental
mutations within this region were found to interfere with
ligand binding, suggesting that it is part of a hydrophobic
ligand-binding pocket (23, 24, 34). Throughout exons D-G, a
variety of deletion and linker insertion mutations of the PR,
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FIG. 2. Amino acid homology among steroid receptors compared by exons. The amino acid sequence of hAR (10) is compared by exon with
amino acid sequences of the hPR, hMR, hGR, and hER (refs. 3-5 and references therein and ref. 6). Indicated are the percent homologies with
hAR (boxed) and amino acid residue numbers (below boxes). Intron/exon splice sites are indicated by the vertical dashed lines. Amino acid
residue numbers of the splice sites ofhAR (this report), hER (14), and the exon B splice sites ofhMR (6) are known. hPR splice sites were derived
from sequence homology with the known splice sites of cPR (17). The splice sites of hGR and the remaining splice sites of hMR were derived
from sequence homology with hAR. Amino acid sequences ofthe predicted splice sites with the exception ofthe exon A/B sites were homologous
(data not shown). Percent homologies among the same exons of different receptors were calculated by the GAP program of the GCG sequence
analysis program (30).
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DNA Hormon
1 559 624676 919
Exons A IBICI D IEIFI W
1~~~~~~~~~~~~~~~~919
hAR oa*864 AspSerVol GOn Pro
GAC TCC GTG CAG CCT
ATG
hAR- AIS aa0856 Asp Ser Met Gln Pro
hGR aa*723 Asp Ser Met His Glu
hMR aa*g29 Asp Ser Met His Asp
hPR aa#878 Asp Asn Leu His Glu
hER aa 5o9 Leu Ile LeuSer His
FIG. 3. Comparison of the mutated AR sequence with other
steroid receptor sequences. Schematic ofthe N-terminal, DNA-, and
hormone-binding domains is depicted with the amino acid residues of
the domain boundaries indicated below. Also shown as a schematic
are the exon boundaries with the location of the point mutation in the
G exon. The mutation of G to A in hAR changed a valine codon to
a methionine codon. Corresponding amino acids within the G exons
of other steroid receptors are shown below. The number of the first
amino acid listed is indicated at the left ofeach sequence. Amino acid
(aa) numbers in hAR (aa 864) and hAR-AIS (aa 856) differ because
of the variation in numbers of glycines and glutamines in exon A.
GR, and ER have been shown to result in decreased steroid
binding and transcriptional activation (23-25).
As a first step in understanding further the structure-
function relationships of AR at the molecular level, we
analyzed a family with complete AIS. For a prototypical
study, we chose a family in which three 46,XY siblings
expressed AR proteins with abnormal ligand-binding prop-
erties (28). Affected individuals had the external female
phenotype typical of complete AIS with adult male levels of
circulating testosterone (31) and normal 5a-reductase activity
in genital skin fibroblasts (28). Saturation binding analysis
with [3H]dihydrotestosterone indicated normal amounts of
AR in genital skin fibroblasts, and the AR protein had a
normal 8S sedimentation rate by sucrose-density centrifuga-
tion (28). However, AR binding affinity for [3H]dihydrotes-
tosterone in affected 46,XY siblings was 3-fold lower than
normal (Kd, 1.5 nM; normal, 0.5 nM) and the binding activity
exhibited increased thermolability (28). Moreover, AR affin-
ity for progesterone was relatively higher than normal (2.5-















testosterone (28). These findings suggested the presence of a
mutation in the AR steroid-binding domain.
Southern blot analysis of genomic DNA with hAR cDNA
probes spanning the coding region revealed no major deletion
in the hAR gene of any member of this family (data not
shown). Northern blot analysis of mRNA from one of the
46,XY siblings with AIS revealed the 7-kb and 10- to 11-kb
mRNA species characteristic ofhAR (data not shown). When
we found no indication of a gross gene deletion or defect
involving mRNA transcription in the three affected siblings of
the present study, sequence analysis was performed to iden-
tify a small deletion or point mutation.
Oligonucleotides (underlined in Fig. 1) bracketing each of
the amino acid coding exons were used as primers for PCR
amplification of genomic DNA from one 46,XY sibling with
complete AIS (II-1). All amplified exons produced fragments
ofpredicted size (data not shown), verifying the Southern and
Northern analyses that indicated the absence of a major hAR
gene deletion. Sequence analysis of amplified exon DNA
revealed a point mutation in exon G of the steroid-binding
domain (Figs. 1, 3, and 4). A guanine residue in the normal
sequence was replaced by adenine, changing amino acid 866
from valine to methionine. No other amino acid sequence
difference from normal was found in the entire 2757-base-pair
AR coding region or in the flanking intron sequences, except
within repeated glutamine and glycine regions of the A exon,
where the numbers of glutamines, 22, and glycines, 15, differ
from normal. However, variation in the numbers of these
repeated amino acids has been found in all published se-
quences of the normal hAR receptor (10-13) and appears to
result from an M13 sequencing artifact (data not shown)
and/or to represent a normal polymorphism.
To confirm the hAR gene mutation, genomic DNA of exon
G from the affected individual was reamplified and se-
quenced. In addition, genomic DNA from the other two
affected siblings (11-2 and II-3) and their mother (I-1) was
analyzed. Each contained the AR allele with a G replaced by
an A, while their carrier mother contained, in addition, the
normal allele (Fig. 4). The valine to methionine alteration is
therefore linked to AIS in this family.
CG dinucleotides, like those found at the locus mutated in
this family with AIS (Figs. 1 and 3), are in humans sometimes
methylated on the cytidine. Methylated cytidine can deam-
inate spontaneously to form thymidine. This may result in
relative hot spots for the formation of mutations like those in
the X chromosome-linked factor VIII gene, which cause
hemophilia A (35).
AR protein was expressed in normal amounts in these
siblings with complete AIS as evidenced by the number of
[3H]dihydrotestosterone-binding sites (28); however, binding
2 '
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FIG. 4. Partial pedigree of a family
with complete AIS and nucleotide se-
quence of the X chromosome-linked mu-
tation. Solid squares indicate 46,XY ge-
netic males with the complete AIS phe-
notype, open square with line indicates
the deceased father, and circle with dot
indicates the heterozygous mother. Ab-
normal AR sequence is shown on the left
and normal sequence is shown on the
right. A single base mutation (asterisk
and arrows) ofG to A resulted in the only
identified amino acid sequence change in
this kindred. The mutation was found in
all amplified G exon clones from individ-
uals 11-1, -2, and -3 and in two of the six
clones sequenced from 1-2. I-2, a hetero-
zygous carrier, displayed the normal al-




Medical Sciences: Lubahn et al.
I %
p %
9538 Medical Sciences: Lubahn et al.
affinity for androgen was decreased.tt There was also a
relative increase in affinity for progesterone. Although hPR
has a leucine at the position corresponding to the AR point
mutation, cPR does contain a methionine, as do hGR and
hMR (Fig. 3). It is interesting to speculate that this region of
the G exon may be important in determining steroid-binding
specificity to AR. Estradiol has no increase in affinity for the
mutated AR (28), and its receptor has little homology with AR
in exon G (Figs. 2 and 3).
The exon G mutation has the potential of affecting both the
steroid-binding and transcription-activating functions of the
AR protein. Ligand binding to AR and other steroid hormone
receptors initiates a transformation process that results in
enhanced binding of receptors to their hormone response
elements (3-5). This process may involve a conformational
change in the receptor protein or separation from a non-
steroid-binding component that unmasks the DNA-binding
domain and a nuclear transfer sequence located in the C-
terminal region downstream from the DNA-binding domain.
The process may also activate within the steroid-binding
domain a dimerization sequence shown to be required for
strong interaction of the steroid receptor with its response
element and for transactivation of gene expression (36, 37).
The mechanism by which this point mutation, resulting in
only a subtle change in steroid-binding properties of the AR,
could cause complete loss ofAR functional activity is not yet
clear. However, it appears that complete transformation of
the receptor subsequent to steroid binding requires precise
structural interaction between receptor and ligand. Steroid
antagonists, for example, have recently been shown to bind
ERs and GRs and promote specific binding to hormone
response elements without enhancing gene transcription as
would a normal agonist (37, 38). Hormone-binding domains
of nuclear receptors are now recognized to have transcrip-
tional enhancer effects (24, 38). A point mutation might
abolish this function without greatly affecting steroid binding.
Expression of this mutated hAR in vitro will allow further
studies to determine whether it is capable of binding to its
response element and enhancing transcription of a reporter
gene.
Present evidence suggests that there is a wide spectrum of
AR gene mutations causing androgen insensitivity syndrome
in humans (1, 2, 20, 21). Such androgen receptor mutations
are amenable to study by using the oligonucleotide primers
and the PCR method described here. This method of analysis,
by allowing correlations of AR structures with AIS pheno-
types, should prove valuable in elucidating the mechanisms
of action ofAR in male sex differentiation and development.
Note Added in Proof. After submission of this paper, we learned of
a publication (39) in which the structural organization of the hAR
gene was partially determined. Their locations for the hAR gene
splice sites are in agreement with the sites we have determined.
ttMore recently, we have recreated the natural mutation (amino acid
866, as shown in Fig. 3) in human AR cDNA by site-directed
mutagenesis and expressed the mutated and wild-type hAR cDNAs
in COS cells by a method previously described (7). Binding affinity
of the mutated AR for 3H-R1881 (a synthetic androgen) was
-4-fold lower than that of the wild-type AR (data not shown). This
difference in androgen-binding affinities is similar to that demon-
strated earlier in cultured genital skin fibroblasts from normal
males and from siblings with AIS in this family (28).
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